(Q38301236)

1 September 2017

1 reference

title

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer (English)

1 reference

1 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Denis M. Collins

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Alex J. Eustace

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

6

B T Hennessy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

3

S Toomey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

J Crown

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

27 December 2014

1 reference

Breast Cancer Research and Treatment

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

5-15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-014-3250-x

12 June 2020

exact match

0 references

cites work

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Lapatinib: functional genomics study leads to insights into mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Recent developments in the maytansinoid antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The immune system and response to HER2-targeted treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Fcgamma receptors as regulators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Engineered protease-resistant antibodies with selectable cell-killing functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3250-X

10.1007/S10549-014-3250-X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 June 2020

1030841286

0 references

Fatcat ID

release_gn4gpia3lncyjfwe4dux63wghi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gn4gpia3lncyjfwe4dux63wghi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25542271%20AND%20SRC:MED&resulttype=core&format=json